SCHEMBL50289

SCHEMBL50289

CCCC[CH]CCCO

nearest known ligand 0.00

⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL120965 0.92 SMN1; SMN2 (0.58)
SCHEMBL28026054 0.92 SMN1; SMN2 (0.58)
SCHEMBL26697594 0.89 TSHR (0.60)
SCHEMBL27311624 0.89 TSHR (0.60)
SCHEMBL28257054 0.89 TSHR (0.60)
SCHEMBL10835848 0.89 TSHR (0.60)
SCHEMBL10412274 0.89 TSHR (0.60)
SCHEMBL11529305 0.89 TSHR (0.60)
SCHEMBL2360901 0.89 TSHR (0.60)
SCHEMBL26697578 0.89 TSHR (0.60)

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 114 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230054591-A1 AGROCHEMICAL GEL COMPOSITIONS MONSANTO TECHNOLOGY LLC 2023-02-23 US claimed
EP-2427172-B1 A METHOD FOR TREATING OVERACTIVE BLADDERS AND A DEVICE FOR STORAGE AND ADMINISTRATION OF TOPICAL OXYBUTYNIN COMPOSITIONS ALLERGAN SALES LLC (US) 2017-11-01 EP claimed
EP-2007378-B1 PHARMACEUTICAL COMPOSITION COMPRISING LIPASE INHIBITOR AND LIPOPHILIC OIL ABSORBENT AND ORAL FORMULATION PREPARED THEREFROM AMOREPACIFIC CORP (KR) 2016-03-30 EP claimed
EP-1565136-B1 COMPOSITIONS FOR TRANSDERMAL OXYBUTYNIN THERAPY WATSON PHARMACEUTICALS INC (US) 2015-02-25 EP claimed
EP-2612629-A1 Compositions for transdermal oxybutynin therapy Watson Pharmaceuticals, Inc. (US) 2013-07-10 EP claimed
EP-2544532-A2 AGROCHEMICAL GEL COMPOSITIONS Monsanto Technology LLC (US) 2013-01-16 EP claimed
US-8246985-B2 Pharmaceutical composition comprising lipase inhibitor and lipophilic oil absorbent and oral formulation prepared therefrom AMOREPACIFIC CORPORATION (KR) 2012-08-21 US claimed
US-8241662-B2 Unoccluded topical oxybutynin gel composition and methods for transdermal oxybutynin therapy WATSON LABORATORIES, INC. (US) 2012-08-14 US claimed
WO-2011113061-A2 AGROCHEMICAL GEL COMPOSITIONS MONSANTO TECHNOLOGY LLC (US) 2011-09-15 WO claimed
US-20090068277-A1 PHARMACEUTICAL COMPOSITION COMPRISING LIPASE INHIBITOR AND LIPOPHILIC OIL ABSORBENT AND ORAL FORMULATION PREPARED THEREFROM AMOREPACIFIC CORPORATION (KR) 2009-03-12 US claimed
EP-2007378-A1 PHARMACEUTICAL COMPOSITION COMPRISING LIPASE INHIBITOR AND LIPOPHILIC OIL ABSORBENT AND ORAL FORMULATION PREPARED THEREFROM Amorepacific Corporation (KR) 2008-12-31 EP claimed
WO-2007123338-A1 PHARMACEUTICAL COMPOSITION COMPRISING LIPASE INHIBITOR AND LIPOPHILIC OIL ABSORBENT AND ORAL FORMULATION PREPARED THEREFROM AMOREPACIFIC CORPORATION (KR) 2007-11-01 WO claimed
WO-2024019936-A1 NANOMATERIALS COMPRISING TRIOLS BEAM THERAPEUTICS INC. (US) 2024-01-25 WO disclosed
EP-4281050-A1 NANOMATERIALS Beam Therapeutics Inc. (US) 2023-11-29 EP disclosed
CN-116761888-A Nanomaterial for the preparation of a nanoparticle 比姆医疗股份有限公司 2023-09-15 CN disclosed
US-11707451-B2 Pharmaceutical composition for modified release ASTELLAS PHARMA INC. (JP) 2023-07-25 US disclosed
EP-0591389-B1 DOSAGE FORM FOR A DELAYED DRUG DELIVERY ALZA CORP (US) 1998-04-15 EP disclosed
EP-0591389-A1 DOSAGE FORM FOR A DELAYED DRUG DELIVERY ALZA CORPORATION (US) 1994-04-13 EP disclosed
WO-1993000071-A1 DOSAGE FORM FOR A DELAYED DRUG DELIVERY ALZA CORPORATION (US) 1993-01-07 WO disclosed
US-4209417-A Perfumed particles and detergent composition containing same THE PROCTER & GAMBLE COMPANY (US) 1980-06-24 US disclosed